INCY
Price
$86.64
Change
+$1.20 (+1.40%)
Updated
Sep 5 closing price
Capitalization
16.92B
57 days until earnings call
RNAC
Price
$10.64
Change
+$0.64 (+6.40%)
Updated
Sep 5 closing price
Capitalization
276.66M
Interact to see
Advertisement

INCY vs RNAC

Header iconINCY vs RNAC Comparison
Open Charts INCY vs RNACBanner chart's image
Incyte
Price$86.64
Change+$1.20 (+1.40%)
Volume$1.39M
Capitalization16.92B
Cartesian Therapeutics
Price$10.64
Change+$0.64 (+6.40%)
Volume$24.44K
Capitalization276.66M
INCY vs RNAC Comparison Chart in %
Loading...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INCY vs. RNAC commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a StrongBuy and RNAC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (INCY: $86.64 vs. RNAC: $10.64)
Brand notoriety: INCY: Notable vs. RNAC: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INCY: 83% vs. RNAC: 41%
Market capitalization -- INCY: $16.92B vs. RNAC: $276.66M
INCY [@Biotechnology] is valued at $16.92B. RNAC’s [@Biotechnology] market capitalization is $276.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCY’s FA Score shows that 1 FA rating(s) are green whileRNAC’s FA Score has 0 green FA rating(s).

  • INCY’s FA Score: 1 green, 4 red.
  • RNAC’s FA Score: 0 green, 5 red.
According to our system of comparison, INCY is a better buy in the long-term than RNAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCY’s TA Score shows that 4 TA indicator(s) are bullish while RNAC’s TA Score has 4 bullish TA indicator(s).

  • INCY’s TA Score: 4 bullish, 4 bearish.
  • RNAC’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, INCY is a better buy in the short-term than RNAC.

Price Growth

INCY (@Biotechnology) experienced а +2.40% price change this week, while RNAC (@Biotechnology) price change was +5.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

INCY is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INCY($16.9B) has a higher market cap than RNAC($277M). INCY has higher P/E ratio than RNAC: INCY (20.48) vs RNAC (1.98). INCY YTD gains are higher at: 25.438 vs. RNAC (-40.592). INCY has higher annual earnings (EBITDA): 1.36B vs. RNAC (-118.73M). INCY has more cash in the bank: 2.42B vs. RNAC (160M). RNAC has less debt than INCY: RNAC (13.3M) vs INCY (42.4M). INCY has higher revenues than RNAC: INCY (4.59B) vs RNAC (1.03M).
INCYRNACINCY / RNAC
Capitalization16.9B277M6,101%
EBITDA1.36B-118.73M-1,141%
Gain YTD25.438-40.592-63%
P/E Ratio20.481.981,036%
Revenue4.59B1.03M446,881%
Total Cash2.42B160M1,514%
Total Debt42.4M13.3M319%
FUNDAMENTALS RATINGS
INCY vs RNAC: Fundamental Ratings
INCY
RNAC
OUTLOOK RATING
1..100
3853
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
39100
PRICE GROWTH RATING
1..100
1083
P/E GROWTH RATING
1..100
10040
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INCY's Valuation (60) in the Biotechnology industry is somewhat better than the same rating for RNAC (100). This means that INCY’s stock grew somewhat faster than RNAC’s over the last 12 months.

INCY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RNAC (100). This means that INCY’s stock grew similarly to RNAC’s over the last 12 months.

INCY's SMR Rating (39) in the Biotechnology industry is somewhat better than the same rating for RNAC (100). This means that INCY’s stock grew somewhat faster than RNAC’s over the last 12 months.

INCY's Price Growth Rating (10) in the Biotechnology industry is significantly better than the same rating for RNAC (83). This means that INCY’s stock grew significantly faster than RNAC’s over the last 12 months.

RNAC's P/E Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for INCY (100). This means that RNAC’s stock grew somewhat faster than INCY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCYRNAC
RSI
ODDS (%)
Bearish Trend 3 days ago
56%
Bullish Trend 3 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
58%
Bullish Trend 3 days ago
85%
Momentum
ODDS (%)
Bullish Trend 3 days ago
60%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
65%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
65%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
61%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 5 days ago
61%
Bullish Trend 14 days ago
83%
Declines
ODDS (%)
Bearish Trend 13 days ago
59%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
66%
Bullish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 3 days ago
62%
Bearish Trend 3 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DRJG0.04N/A
N/A
DRJ International Group Limited Inc.
PFBX19.84N/A
N/A
Peoples Financial Corp.
NAPRF303.80N/A
N/A
Naspers Ltd.
TCLAF14.74N/A
N/A
Transcontinental Inc.
VLMTY37.10N/A
N/A
Valmet OYJ

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with TECH. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then TECH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
+1.40%
TECH - INCY
40%
Loosely correlated
+2.82%
REGN - INCY
38%
Loosely correlated
+1.09%
RPRX - INCY
37%
Loosely correlated
-2.25%
AGIO - INCY
36%
Loosely correlated
-0.33%
RNAC - INCY
36%
Loosely correlated
+6.40%
More

RNAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with NCNA. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then NCNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
+6.40%
NCNA - RNAC
92%
Closely correlated
+0.35%
NBY - RNAC
91%
Closely correlated
-11.61%
TAOX - RNAC
91%
Closely correlated
+6.91%
SNGX - RNAC
89%
Closely correlated
-5.92%
KPRX - RNAC
89%
Closely correlated
-1.83%
More